Europharma, a subsidiary of CFAO group, a multinational company engaged in the sale of manufactured pharmaceutical products in Africa, has just signed a partnership agreement with Sanofi which will start operating in June 2017. The objective is to boost and promote the development of Maphar, the Moroccan subsidiary of Sanori in the African market, Le Figaro reports. Eurapharma will be granted 51% of Maphar's stake, a promotion plan for the Moroccan and African markets, and cooperation between Euraphama, Sanofi Maroc and Maphar. Sanofi holds 49% of the capital of Maphar and will remain a shareholder of reference, specifies the same source. The Group will also strengthen its position as a leader in the Moroccan pharmaceutical market through its Sanofi-Aventis Morocco subsidiary, which has made significant industrial, logistical and scientific investments in recent years. «The partnership with Eurapharma, the leading pharmaceutical retailer in Africa, is in line with Maphar's strategy and ambitions to continue its development in Morocco and to improve the quality of customer service both in terms of production and distribution», Rejoices Amine Benabderrazik, CEO of Sanofi's activities in Morocco. «Thanks to this partnership, the presence of Sanofi in Morocco is reinforced by additional expertise», he added.
